Psoriatic Arthritis

Study shows there is no substantial difference in cardiovascular risk associated with different biologic therapies for psoriasis and psoriatic arthritis patients.

In this slideshow, we address the treatment recommendations for adults with active psoriatic arthritis despite previous treatment with biologics.

The 2018 American College of Rheumatology and the National Psoriasis Foundation released updated treatment guidelines for psoriatic arthritis (PsA). Test your knowledge of the current therapeutic recommendations for PsA in this quiz.

Biological therapies prescribed for rheumatic diseases may also reduce their long-term risks of cardiovascular diseases (CVD), new research shows.

A new study in JAMA Dermatology raises an interesting question for physicians who treat psoriasis patients. Does methotrexate work best in patients with plaque psoriasis alone or patients who have both psoriasis and arthritis?

Calprotectin is a known marker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Now, researchers reporting in Arthritis Research and Therapy say that baseline calprotectin levels may predict disease relapse for RA and PsA patients on TNFi therapy. Learn more in this slideshow. 

The January issue of Arthritis and Rheumatology includes updated treatment guidelines for adults with active psoriatic arthritis. In this article, we take a comprehensive look at the guidelines.

The immunosuppressive drug was more effective and resulted in fewer adverse events in patients with psoriasis but without psoriatic arthritis.

New joint guidelines by the American College of Rheumatology and National Psoriasis Foundation recommend psoriatic arthritis patients receive a treat-to-target approach, first-line use of tumor necrosis factor inhibitors biologics, and smoking cessation.

How much confidence do you have in your treatment target?

Take this 5-question quiz to find out.

The approval was based on a comprehensive data package demonstrating that Hyrimoz matches the reference biologic in terms of safety, efficacy, and quality.

Does interval training have a place in the management of PsA?

But cardiovascular risk is similar to that seen in patients with psoriasis.

New data supports the use of etanercept as a monotherapy, or in combination, for the treatment of psoriatic arthritis.

British researchers quantified the burden of continuing weight gain on the risk of PsA.

You can expect to see more bony erosion and enthesiophyte growth in your patients with PsA than in those with isolated psoriasis.

Be cautious about relying heavily on inflammatory back pain criteria that were developed for ankylosing spondylitis.

Here: the impact of vitamin D, the Mediterranean diet, and psychological stress on disease severity.

An international research team compared the Physician’s Global Assessment with separate evaluations of skin and musculoskeletal disease activity in PsA.

Is an innate biologic effect responsible for a better response to TNF inhibitors in men?

New recommendations from the National Psoriasis Foundation offer answers. The express goal of these guidelines: to reduce disease severity through proper nutrition.

Two characteristics predict a worse response to biologics.

Two recent studies focus on the risks of osteoporosis and cardiovascular disease in patients on the psoriatic arthritis/psoriasis spectrum.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.